Prospects for genetic intervention in primary open-angle glaucoma

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Recent advances in glaucoma genetics hold potential for dramatically changing the clinical care of glaucoma patients. To date, 5 primary open-angle glaucoma genes and 2 congenital glaucoma genes have been mapped. As more glaucoma genes are identified, earlier diagnosis for glaucoma should become more readily available. Progress in molecular genetics holds considerable promise for both current and future therapy of glaucoma. Glaucoma classification will be tailored to each individual based upon that person's family history, i.e. family glaucoma genotype. In the future, the optimum treatment for a specific glaucoma patient might rely on the knowledge of the phenotype of that person's causal gene, without having to resort to 'trial and error'. At this time, glaucoma treatment is restricted to lowering intraocular pressure. In the near future, with the knowledge of the pathophysiology caused by the defective glaucoma gene, more traditional drug treatments may be used to bypass the gene defect. Ultimately, gene therapy would replace the mutant gene with a normal one before visual loss has occurred as has been done with a model for retinitis pigmentosa, the retinal degeneration mouse.

Original languageEnglish (US)
Pages (from-to)333-340
Number of pages8
JournalDrugs and Aging
Volume13
Issue number5
StatePublished - 1998

Fingerprint

Genetic Engineering
Glaucoma
Genes
Primary Open Angle Glaucoma
Retinal Degeneration
Retinitis Pigmentosa
Therapeutics
Intraocular Pressure
Genetic Therapy
Molecular Biology
Early Diagnosis
Patient Care
Genotype
Phenotype

ASJC Scopus subject areas

  • Pharmacology
  • Geriatrics and Gerontology

Cite this

Prospects for genetic intervention in primary open-angle glaucoma. / Wirtz, Mary; Acott, Ted; Samples, John R.; Morrison, John.

In: Drugs and Aging, Vol. 13, No. 5, 1998, p. 333-340.

Research output: Contribution to journalArticle

@article{c85644504c4842549f983cc92a65637a,
title = "Prospects for genetic intervention in primary open-angle glaucoma",
abstract = "Recent advances in glaucoma genetics hold potential for dramatically changing the clinical care of glaucoma patients. To date, 5 primary open-angle glaucoma genes and 2 congenital glaucoma genes have been mapped. As more glaucoma genes are identified, earlier diagnosis for glaucoma should become more readily available. Progress in molecular genetics holds considerable promise for both current and future therapy of glaucoma. Glaucoma classification will be tailored to each individual based upon that person's family history, i.e. family glaucoma genotype. In the future, the optimum treatment for a specific glaucoma patient might rely on the knowledge of the phenotype of that person's causal gene, without having to resort to 'trial and error'. At this time, glaucoma treatment is restricted to lowering intraocular pressure. In the near future, with the knowledge of the pathophysiology caused by the defective glaucoma gene, more traditional drug treatments may be used to bypass the gene defect. Ultimately, gene therapy would replace the mutant gene with a normal one before visual loss has occurred as has been done with a model for retinitis pigmentosa, the retinal degeneration mouse.",
author = "Mary Wirtz and Ted Acott and Samples, {John R.} and John Morrison",
year = "1998",
language = "English (US)",
volume = "13",
pages = "333--340",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Prospects for genetic intervention in primary open-angle glaucoma

AU - Wirtz, Mary

AU - Acott, Ted

AU - Samples, John R.

AU - Morrison, John

PY - 1998

Y1 - 1998

N2 - Recent advances in glaucoma genetics hold potential for dramatically changing the clinical care of glaucoma patients. To date, 5 primary open-angle glaucoma genes and 2 congenital glaucoma genes have been mapped. As more glaucoma genes are identified, earlier diagnosis for glaucoma should become more readily available. Progress in molecular genetics holds considerable promise for both current and future therapy of glaucoma. Glaucoma classification will be tailored to each individual based upon that person's family history, i.e. family glaucoma genotype. In the future, the optimum treatment for a specific glaucoma patient might rely on the knowledge of the phenotype of that person's causal gene, without having to resort to 'trial and error'. At this time, glaucoma treatment is restricted to lowering intraocular pressure. In the near future, with the knowledge of the pathophysiology caused by the defective glaucoma gene, more traditional drug treatments may be used to bypass the gene defect. Ultimately, gene therapy would replace the mutant gene with a normal one before visual loss has occurred as has been done with a model for retinitis pigmentosa, the retinal degeneration mouse.

AB - Recent advances in glaucoma genetics hold potential for dramatically changing the clinical care of glaucoma patients. To date, 5 primary open-angle glaucoma genes and 2 congenital glaucoma genes have been mapped. As more glaucoma genes are identified, earlier diagnosis for glaucoma should become more readily available. Progress in molecular genetics holds considerable promise for both current and future therapy of glaucoma. Glaucoma classification will be tailored to each individual based upon that person's family history, i.e. family glaucoma genotype. In the future, the optimum treatment for a specific glaucoma patient might rely on the knowledge of the phenotype of that person's causal gene, without having to resort to 'trial and error'. At this time, glaucoma treatment is restricted to lowering intraocular pressure. In the near future, with the knowledge of the pathophysiology caused by the defective glaucoma gene, more traditional drug treatments may be used to bypass the gene defect. Ultimately, gene therapy would replace the mutant gene with a normal one before visual loss has occurred as has been done with a model for retinitis pigmentosa, the retinal degeneration mouse.

UR - http://www.scopus.com/inward/record.url?scp=0031726381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031726381&partnerID=8YFLogxK

M3 - Article

C2 - 9829162

AN - SCOPUS:0031726381

VL - 13

SP - 333

EP - 340

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 5

ER -